. 2021 Nov 29;22(23):12916. doi: 10.3390/ijms222312916

Table 1.

Ongoing clinical trials targeting Rho-kinase in various indications ¹.

Drug	NCT Number	Indication	Phase	Status	Note
AR-12286 (Verosudil)	NCT01330979	Open Angle Glaucoma, Ocular Hypertension (OH)	2	Completed
	NCT01699464	Open Angle Glaucoma, Ocular Hypertension (OH)	2	Completed
	NCT01936389	Exfoliation Syndrome, OH, Open Angle Glaucoma	2	Unknown
	NCT02174991	Glaucoma	2	Unknown
	NCT01060579	Glaucoma	2	Completed
	NCT02173223	Advanced Glaucoma	2	Unknown
	NCT02152774	Chronic Angle-closure Glaucoma	2	Unknown
	NCT00902200	Elevated Intraocular Pressure	2	Completed
	NCT01302249	Glaucoma, OH	2	Completed	Latanoprost
	NCT01474135	Glaucoma, OH	2	Completed	Travoprost
Fasudil		Cerebral Vasospasm, Cerebral Ischemic Symptoms	Approved in Japan (June, 1995)
	NCT01935518	Amyotrophic Lateral Sclerosis	2	Unknown
	NCT03792490	Amyotrophic Lateral Sclerosis	2	Recruiting
	NCT00670202	Carotid Stenosis	2	Terminated
	NCT04734379	Progressive Supranuclear Palsy, Corticobasal Syndrome	2	Recruiting
	NCT04191954	Retinopathy of Prematurity	2/3	Recruiting
	NCT04793659	Dementia	2	Active, not recruiting
	NCT00498615	Raynaud’s Disease, Scleroderma	3	Completed
	NCT01823081	Diabetic Macular Edema	3	Completed
	NCT03753269	ST Segment Elevation, Myocardial Infarction	4	Not yet recruiting
	NCT00120718	Atherosclerosis, Hypercholesterolemia	2	Completed
	NCT03404843	Cardiovascular Diseases	2	Completed
	NCT03391219	Retinal Vein Occlusion	2/3	Unknown	bevacizumab
	NCT04734379	Progressive Supranuclear Palsy, Sorticobasal Syndrome	2	Recruiting
Ripasudil		Glaucoma, OH	Approved in Japan (September, 2014)
	NCT03575130	Fuchs’ Endothelial Dystrophy, Fuchs Dystrophy, Corneal Endothelial Dystrophy, Corneal Endothelial Cell Loss, Cornea Guttata	2	Unknown
	NCT03813056	Fuchs’ Endothelial Dystrophy	2	Recruiting
	NCT03249337	Fuchs’ Endothelial Dystrophy	4	Recruiting
	NCT04621136	Retinopathy of Prematurity	1/2	Recruiting
Netarsudil		Open-Angle glaucoma, OH	Approved (2019)		Latanoprost
	NCT04057053	Fuchs’ Endothelial Dystrophy, Cataract	Early 1	Completed
	NCT04752020	Fuchs’ Endothelial Dystrophy	Early 1	Recruiting
	NCT03248037	Fuchs’ Endothelial Dystrophy, Bullous Keratopathy	3	Completed
	NCT04620135	Primary Open Angle Glaucoma, OH	3	Completed
	NCT03233308	Primary Open Angle Glaucoma, OH	2	Completed
	NCT04064918	Open-Angle Glaucoma, OH	Not applicable	Not yet recruiting
	NCT02558374		3	Completed
	NCT02874846		2	Completed
	NCT02246764	OH, Glaucoma	3	Completed
	NCT04498169	Corneal Edema	2	Completed
KD025 (Belumosudil)		Chronic Graft-Versus-Host Disease (cGVHD)	Approved (2021)
	NCT03640481	cGVHD	2	Recruiting
	NCT02841995	GVHD	2	Active, not recruiting
	NCT02317627	Psoriasis Vulgaris	2	Completed
	NCT02106195	Psoriasis Vulgaris	2	Completed
	NCT03907540	Autoimmune Diseases, Fibrosis	1	Completed
	NCT02688647	Idiopathic Pulmonary Fibrosis	2	Completed
	NCT03919799	Systemic Sclerosis, Diffuse Cutaneous Systemic Sclerosis	2	Recruiting
	NCT04166942	Hepatic Impairment	1	Recruiting
AT13148 ²	NCT01585701	Advanced Solid Tumor	1	Completed

¹ Data in this table are based on the advanced search of the Rho-kinase inhibitor except AT13148 on the NIH ClinicalTrials.gov site. (https://clinicaltrials.gov/, accessed on 19 October 2021) ² AT13148 is applied to a clinical trial as a novel cyclic adenosine monophosphate (cAMP)-dependent, cyclic guanosine monophosphate (cGMP)-dependent, and protein kinase C (AGC) inhibitor.